pharma · Opioid Use Disorder · Opioid Dependence
Indivior Pty
Indivior Pty Ltd
Indivior is a pharma organization headquartered in Richmond, USA. Primary therapeutic focus areas include Opioid Use Disorder, Opioid Dependence, Schizophrenia, Opioid Dependency, Opiate Dependence. NovaPharmaNews links
., Richmond, VA, US HQ
967 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- ., Richmond, VA, US
- Employees
- 967
- Programs
- 39
- Drugs
- 19
- Patents
- 34
2.0mg Buprenorphine/0.5mg Naloxone
Approved · small molecule · Hepatic Failure
2.0mg Buprenorphine/0.5mg Naloxone for Hepatic Failure is a Approved program (small_molecule) at Indivior Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code RB-US-08-0003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Indivior Pty Ltd
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Hepatic Failure
- Status
- completed
- Trials
- 1